{"id":60999,"date":"2024-02-28T07:19:36","date_gmt":"2024-02-28T07:19:36","guid":{"rendered":"https:\/\/medsname.com\/aldactone\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"aldactone","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/aldactone\/","title":{"rendered":"Aldactone"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Aldactone?<\/h3>\n

Aldactone<\/strong> je 25 \/ 50 \/ 100 mg spironolactone tablet<\/strong> from RPG Life Sciences — a mineralocorticoid receptor antagonist (aldosterone antagonist)<\/strong> kter\u00fd p\u016fsob\u00ed na mineralocorticoid receptor (MR) in the principal cells of the cortical collecting duct<\/strong>. Spironolactone was introduced by G.D. Searle in 1959 — designed as a synthetic steroid to antagonise aldosterone’s distal-tubule effect on sodium retention and potassium excretion. The first MR antagonist; remains the reference agent despite the availability of the more selective eplerenone. Half-life 1.4 hours (parent); 16-24 hours (active metabolites canrenone and 7-\u03b1-thiomethylspirolactone); onset 24-48 hours (needs time for receptor antagonism to manifest at the tissue level); peak effect 2-3 days; duration 2-3 days after discontinuation. Primary indication: heart failure with reduced ejection fraction (HF-REF), primary aldosteronism, resistant hypertension, cirrhotic ascites, adjunct treatment for hirsutism and PCOS<\/strong>. Typick\u00e9 d\u00e1vkov\u00e1n\u00ed: Rezistentn\u00ed hypertenze<\/strong> (BP not controlled on ACEi\/ARB + CCB + thiazide): 25-50 mg once daily — PATHWAY-2 evidence. Spironolactone beats bisoprolol and doxazosin as the fourth agent in resistant HTN. Nen\u00ed l\u00e9kem prvn\u00ed volby p\u0159i hypertenzi.<\/strong> Primary aldosteronism (Conn’s):<\/strong> 50-400 mg\/day until potassium and BP normalise, then maintenance 25-100 mg. Key contraindications: see full list below. Monitor electrolytes, creatinine, and glucose. Nekombinujte s lithiem<\/strong> (thiazidov\u00e1\/smy\u010dkov\u00e1 diuretika mohou vyvolat toxicitu lithia). U\u017eit\u00ed v t\u011bhotenstv\u00ed je p\u0159\u00edpad od p\u0159\u00edpadu<\/strong> (viz pozn\u00e1mka k t\u011bhotenstv\u00ed). U v\u011bt\u0161iny hypertonik\u016f funguj\u00ed diuretika nejl\u00e9pe jako druh\u00fd nebo t\u0159et\u00ed l\u00e9k<\/strong> \u2014 obvykle v kombinaci s ARB, ACE inhibitorem nebo blok\u00e1torem kalciov\u00fdch kan\u00e1l\u016f sp\u00ed\u0161e ne\u017e samostatn\u011b.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

What Is Aldactone?<\/h2>\n

Aldactone is an oral 25 \/ 50 \/ 100 mg spironolactone tablet from RPG Life Sciences, supplied in 30-180 tablets. Spironolactone was introduced by G.D. Searle in 1959 — designed as a synthetic steroid to antagonise aldosterone’s distal-tubule effect on sodium retention and potassium excretion. The first MR antagonist; remains the reference agent despite the availability of the more selective eplerenone.<\/p>\n

How Spironolactone Works<\/h2>\n

Spironolactone inhibits the mineralocorticoid receptor (MR) in the principal cells of the cortical collecting duct<\/strong>. N\u00e1sledn\u00e9 \u00fa\u010dinky:<\/p>\n

    \n
  • Blocks aldosterone at the mineralocorticoid receptor<\/strong> in principal cells of the cortical collecting duct<\/li>\n
  • Reduced sodium reabsorption, reduced potassium secretion<\/strong> \u2014 m\u00edrn\u00e1 natriur\u00e9za se zadr\u017eov\u00e1n\u00edm drasl\u00edku (\u0161et\u0159\u00edc\u00ed drasl\u00edk)<\/li>\n
  • Anti-fibrotic and anti-remodelling effect in myocardium<\/strong> — aldosterone drives cardiac fibrosis independent of its salt-retaining effect; blocking the receptor reduces fibrosis. This is the main mechanism of the HF-REF mortality benefit (RALES).<\/li>\n
  • Anti-androgen activity<\/strong> — cross-reactivity with androgen and progesterone receptors produces gynaecomastia and menstrual irregularity as class side effects; same activity gives its off-label role in hirsutism and PCOS.<\/li>\n
  • Delayed onset\/offset<\/strong> (24-72 hours each direction) — receptor pharmacology plus long-acting active metabolites (canrenone)<\/li>\n
  • Effective at resistant hypertension<\/strong> (PATHWAY-2) — acts on the subpopulation of hypertensives with covert aldosterone excess<\/li>\n<\/ul>\n

    Schv\u00e1len\u00e9 a v\u011bdecky podlo\u017een\u00e9 indikace<\/h2>\n
      \n
    • Heart failure with reduced ejection fraction (HF-REF), primary aldosteronism, resistant hypertension, cirrhotic ascites, adjunct treatment for hirsutism and PCOS<\/strong> \u2014 prim\u00e1rn\u00ed indikace<\/li>\n
    • Heart failure with reduced ejection fraction (EF ≤35%)<\/strong> — RALES evidence, 25-50 mg daily<\/li>\n
    • Primary aldosteronism (Conn’s syndrome)<\/strong> — definitive medical therapy for bilateral adrenal hyperplasia; bridging therapy for unilateral adenoma pre-surgery<\/li>\n
    • Rezistentn\u00ed hypertenze<\/strong> — PATHWAY-2 evidence; fourth-line agent after ACEi\/ARB + CCB + thiazide<\/li>\n
    • Cirrhotic ascites<\/strong> — first-line diuretic in cirrhosis (loop diuretics added if response inadequate)<\/li>\n
    • Hirsutism, PCOS-related acne, female-pattern hair loss<\/strong> — off-label anti-androgen therapy<\/li>\n
    • Post-MI with LV dysfunction<\/strong> — eplerenone is preferred (EPHESUS trial specific)<\/li>\n<\/ul>\n

      Kl\u00ed\u010dov\u00e9 d\u016fkazy z klinick\u00fdch studi\u00ed:<\/strong> RALES (1999)<\/strong> — landmark trial of spironolactone 25-50 mg in severe HF-REF; 30% reduction in all-cause mortality. Established aldosterone antagonism as standard HF-REF therapy. EPHESUS<\/strong> a EMPHASIS-HF<\/strong> extended to eplerenone. PATHWAY-2 (2015)<\/strong> — spironolactone 25-50 mg was the most effective fourth agent for resistant hypertension vs bisoprolol or doxazosin. TOPCAT<\/strong> — modest benefit in HF with preserved ejection fraction (HF-PEF); signal stronger in Americas arm than Russia arm (controversial).<\/p>\n

      Aldactone Dosage<\/h2>\n

      Heart dose:<\/strong> Rezistentn\u00ed hypertenze<\/strong> (BP not controlled on ACEi\/ARB + CCB + thiazide): 25-50 mg once daily — PATHWAY-2 evidence. Spironolactone beats bisoprolol and doxazosin as the fourth agent in resistant HTN. Nen\u00ed l\u00e9kem prvn\u00ed volby p\u0159i hypertenzi.<\/strong> Primary aldosteronism (Conn’s):<\/strong> 50-400 mg\/day until potassium and BP normalise, then maintenance 25-100 mg.<\/p>\n

      Dal\u0161\u00ed indikace:<\/strong> Heart failure with reduced ejection fraction (EF ≤35%):<\/strong> 12.5-25 mg once daily; target 25-50 mg if tolerated (RALES trial). Cirrhotic ascites:<\/strong> 50-400 mg\/day, usually with furosemide 20-160 mg (1:2.5 ratio); target 0.5 kg\/day weight loss. Hirsutism \/ PCOS \/ acne (female patients):<\/strong> 50-200 mg\/day — suppresses androgen-driven hair growth and acne over 3-6 months (off-label but well-established).<\/p>\n

      Pod\u00e1v\u00e1n\u00ed:<\/strong> jednou denn\u011b (nebo dvakr\u00e1t denn\u011b u vysok\u00fdch d\u00e1vek kli\u010dkov\u00fdch diuretik p\u0159i srde\u010dn\u00edm selh\u00e1n\u00ed), r\u00e1no. Ve\u010dern\u00ed pod\u00e1v\u00e1n\u00ed zp\u016fsobuje nykturii a m\u011blo by b\u00fdt pokud mo\u017eno vynech\u00e1no. U\u017e\u00edvejte ve stejnou denn\u00ed dobu. Potrava v\u00fdznamn\u011b neovliv\u0148uje vst\u0159eb\u00e1v\u00e1n\u00ed \u017e\u00e1dn\u00e9ho z t\u011bchto diuretik.<\/p>\n

      Monitorovac\u00ed pl\u00e1n:<\/strong><\/p>\n